1. Scrip
  2. >>Rare Diseases

Sobi Ramps Up In Rare Diseases With Apellis Deal

$250m Upfront Fee For Rights To Pegcetacoplan

 
• By Kevin Grogan

Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.

US dollars
Sobi spending big to boost portfolio • Source: Archive

Swedish Orphan Biovitrum AB is pressing on with plans to diversify the pipeline beyond its core hemophilia franchise and has licensed rights to Apellis Pharmaceuticals, Inc.'s pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases including paroxysmal nocturnal hemoglobinuria (PNH).

The complex pact will see Sobi pay an upfront fee of $250m plus $80m in development reimbursement to Apellis and up to $915m in other regulatory and commercial milestone payments, to support the initial development plan for pegcetacoplan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.